10:31 AM EDT, 05/13/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Monday that it has received approval for Orladeyo from Mexico's Federal Commission for Protection against Health Risks for the prophylaxis of hereditary angioedema attacks in patients 12 years of age or older.

The company has a partnership with Pint Pharma for registration and promotion of Orladeyo in the pan-Latin America region, BioCryst said. Orladeyo has been approved by regulatory agencies in Chile, Argentina and Brazil.

Price: 5.41, Change: +0.09, Percent Change: +1.69